Published in BMC Immunol on March 18, 2008
Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med (1996) 9.31
TLR signaling pathways. Semin Immunol (2004) 9.08
T cell anergy. Annu Rev Immunol (2001) 7.15
Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol (1995) 6.09
Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature (1997) 5.80
Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol (2002) 4.64
Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med (2004) 4.34
Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol (2004) 3.12
Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med (2002) 3.02
Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J Immunol (2003) 2.34
Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol (2000) 2.30
High-level IL-12 production by human dendritic cells requires two signals. Int Immunol (1998) 2.15
Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res (2005) 2.06
CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A (1999) 1.98
Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol (1999) 1.68
Activation of toll-like receptor 3 protects against DSS-induced acute colitis. Inflamm Bowel Dis (2007) 1.57
Phenotypic characterization of five dendritic cell subsets in human tonsils. Am J Pathol (2001) 1.49
Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with respiratory syncytial virus and other viral respiratory infections. J Infect Dis (2005) 1.46
Cutting Edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-beta. J Immunol (2006) 1.36
Increased number of mature dendritic cells in Crohn's disease: evidence for a chemokine mediated retention mechanism. Gut (2005) 1.30
Suppression of the effector phase of inflammatory arthritis by double-stranded RNA is mediated by type I IFNs. J Immunol (2007) 1.30
Induction of antigen-specific human CD4(+) T cell anergy by peripheral blood DC2 precursors. Eur J Immunol (2001) 1.26
A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. Blood (2000) 1.26
Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci U S A (2004) 1.24
Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res (2005) 1.11
Regulatory T cells and transplantation tolerance. Hum Immunol (2006) 1.09
Rheumatoid arthritis synovium contains plasmacytoid dendritic cells. Arthritis Res Ther (2005) 1.08
Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer (2007) 1.08
Heterogeneity of freshly isolated human tonsil dendritic cells demonstrated by intracellular markers, phagocytosis, and membrane dye transfer. Cytometry (2002) 1.08
Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen-specific T lymphocytes. Eur J Immunol (2000) 1.06
The interplay of dendritic cell subsets in systemic lupus erythematosus. Immunol Cell Biol (2002) 1.04
Phase I-II trials of poly IC stabilized with poly-L-lysine. Cancer Treat Rep (1978) 1.00
Analysis of plasmacytoid and myeloid dendritic cells in nasal epithelium. Clin Vaccine Immunol (2006) 0.97
Dendritic cells: key cells for the induction of regulatory T cells? Curr Top Microbiol Immunol (2005) 0.95
Standardized generation of fully mature p70 IL-12 secreting monocyte-derived dendritic cells for clinical use. Cancer Immunol Immunother (2001) 0.95
Plasmacytoid dendritic cells (PDC) are the major DC subset innately producing cytokines in human lymph nodes. J Leukoc Biol (2005) 0.95
The morphology, immunophenotype and distribution of paracortical dendritic leucocytes in lymph nodes regional to cutaneous melanoma. Melanoma Res (2001) 0.90
Respiratory tolerance in the protection against asthma. Curr Drug Targets Inflamm Allergy (2003) 0.88
Identification and characterization of intestinal Peyer's patch interferon-alpha producing (plasmacytoid) dendritic cells. Hum Immunol (2004) 0.88
Presence and maturity of dendritic cells in melanoma lymph node metastases. J Pathol (2005) 0.81
Langerhans cells differentiation: a three-act play. Ital J Anat Embryol (2001) 0.79
Are thymus-derived lymphocytes (T cells) defective in the nasopharyngeal and palatine tonsils of children? Otolaryngol Head Neck Surg (1993) 0.77
An approach to understanding the transmission of Mycobacterium leprae using molecular and immunological methods: results from the MILEP2 study. Int J Lepr Other Mycobact Dis (2004) 1.82
Clinical and pathologic characteristics of biopsy-proven iris melanoma: a multicenter international study. Arch Ophthalmol (2011) 1.78
Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol (2002) 1.67
Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res (2010) 1.59
The heterogeneous distribution of monosomy 3 in uveal melanomas: implications for prognostication based on fine-needle aspiration biopsies. Arch Pathol Lab Med (2007) 1.50
Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci (2011) 1.37
Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles. Exp Eye Res (2005) 1.37
Vascular endothelial growth factor a in eyes with uveal melanoma. Arch Ophthalmol (2006) 1.33
Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci (2002) 1.33
Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Arch (2012) 1.24
Cancer cell adaptation to chemotherapy. BMC Cancer (2005) 1.21
Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma. Invest Ophthalmol Vis Sci (2008) 1.18
Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. Invest Ophthalmol Vis Sci (2010) 1.18
In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages. J Immunol (2010) 1.15
Locality Sensitive Deep Learning for Detection and Classification of Nuclei in Routine Colon Cancer Histology Images. IEEE Trans Med Imaging (2016) 1.12
Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer (2003) 1.11
Patterns of expression of DNA repair genes and relapse from melanoma. Clin Cancer Res (2010) 1.09
Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol Vis Sci (2008) 1.08
Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements. Methods Mol Med (2005) 1.03
Authenticating cell lines in ophthalmic research laboratories. Invest Ophthalmol Vis Sci (2008) 1.03
A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma. J Immunol (2007) 1.01
Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression. PLoS One (2012) 1.01
Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC). BMC Cancer (2009) 1.00
Regulation of VEGF-A in uveal melanoma. Invest Ophthalmol Vis Sci (2009) 1.00
Virus-specific CTL responses induced by an H-2K(d)-restricted, motif-negative 15-mer peptide from the fusion protein of respiratory syncytial virus. J Gen Virol (2002) 0.99
Angiopoietin modulation of vascular endothelial growth factor: Effects on retinal endothelial cell permeability. Cytokine (2007) 0.98
Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. Int J Cancer (2003) 0.98
Role of TRAIL and IFN-gamma in CD4+ T cell-dependent tumor rejection in the anterior chamber of the eye. J Immunol (2003) 0.96
Epigenetic inactivation of RASSF1a in uveal melanoma. Invest Ophthalmol Vis Sci (2007) 0.95
Heat shock protein expression in the eye and in uveal melanoma. Invest Ophthalmol Vis Sci (2003) 0.95
Effect of heterogeneous distribution of monosomy 3 on prognosis in uveal melanoma. Arch Pathol Lab Med (2011) 0.95
Macrophages are vital in spontaneous intraocular tumor eradication. Invest Ophthalmol Vis Sci (2006) 0.94
The molecular basis of the chemosensitivity of metastatic cutaneous melanoma to chemotherapy. J Clin Pathol (2010) 0.94
Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA). Anticancer Drugs (2003) 0.94
The effect of pentamidine on melanoma ex vivo. Anticancer Drugs (2010) 0.91
Epigenetic silencing of MHC2TA transcription in cancer. Biochem Pharmacol (2006) 0.91
Inflammatory cytokines in eyes with uveal melanoma and relation with macrophage infiltration. Invest Ophthalmol Vis Sci (2010) 0.91
The value of combining anterior segment fluorescein angiography with indocyanine green angiography in scleral inflammation. Ophthalmology (2003) 0.91
Factors affecting the epidemiology of Acanthamoeba keratitis. Ophthalmic Epidemiol (2007) 0.90
Whole-body bioluminescent imaging of human uveal melanoma in a new mouse model of local tumor growth and metastasis. Invest Ophthalmol Vis Sci (2005) 0.89
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC Cancer (2004) 0.88
Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. J Immunol (2008) 0.88
Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay. Anticancer Drugs (2005) 0.88
High-throughput screening of natural products for cancer therapy. Planta Med (2010) 0.87
Heterogeneity of chemosensitivity of esophageal and gastric carcinoma. Anticancer Drugs (2003) 0.87
Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines. Anticancer Drugs (2006) 0.87
Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma. Invest Ophthalmol Vis Sci (2002) 0.87
Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study. Anticancer Drugs (2003) 0.87
The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples. Mol Cancer Ther (2004) 0.87
Uveal melanoma: the inflammatory microenvironment. J Innate Immun (2012) 0.87
Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. Invest Ophthalmol Vis Sci (2012) 0.87
Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus. BMC Cancer (2006) 0.86
Prognostic value of S-100-beta serum concentration in patients with uveal melanoma. Arch Ophthalmol (2003) 0.86
Melanoma vaccines: The problems of local immunosuppression. Hum Immunol (2009) 0.86
In vivo confocal microscopy of trachoma in relation to normal tarsal conjunctiva. Ophthalmology (2010) 0.85
Proteomic analysis of uveal melanoma reveals novel potential markers involved in tumor progression. Invest Ophthalmol Vis Sci (2006) 0.85
Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma. J Immunol (2012) 0.85
Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma. Oncology (Williston Park) (2005) 0.85
Recurrence of treated ciliary body melanoma following trabeculectomy. Clin Experiment Ophthalmol (2009) 0.84
Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction. J Immunol (2004) 0.84
A fish scale-derived collagen matrix as artificial cornea in rats: properties and potential. Invest Ophthalmol Vis Sci (2013) 0.84
Uveal and cutaneous melanoma: shared expression characteristics of melanoma-associated antigens. Invest Ophthalmol Vis Sci (2005) 0.84
Expression of CD133 and other putative stem cell markers in uveal melanoma. Melanoma Res (2011) 0.83
A comparison of methods for EGFR mutation testing in non-small cell lung cancer. Diagn Mol Pathol (2013) 0.83
Expression of Wnt5a and its downstream effector beta-catenin in uveal melanoma. Melanoma Res (2007) 0.83
Epigenetic regulation identifies RASEF as a tumor-suppressor gene in uveal melanoma. Invest Ophthalmol Vis Sci (2008) 0.83
ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials. Recent Results Cancer Res (2003) 0.83
Cell sensitivity assays: the ATP-based tumor chemosensitivity assay. Methods Mol Biol (2011) 0.83
Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay. BMC Cancer (2009) 0.83
Evidence for natural killer cell-mediated protection from metastasis formation in uveal melanoma patients. Invest Ophthalmol Vis Sci (2009) 0.82
Ex vivo reversal of chemoresistance by tariquidar (XR9576). Anticancer Drugs (2004) 0.82
Maintenance of immune tolerance depends on normal tissue homeostasis. J Immunol (2005) 0.82
Bevacizumab and intraocular tumors: an intriguing paradox. Mol Vis (2012) 0.82
Long-term follow-up after submandibular gland transplantation in severe dry eyes secondary to cicatrizing conjunctivitis. Am J Ophthalmol (2010) 0.82
Impact of tumor-associated macrophages in LH(BETA)T(AG) mice on retinal tumor progression: relation to macrophage subtype. Invest Ophthalmol Vis Sci (2010) 0.81
Presence and maturity of dendritic cells in melanoma lymph node metastases. J Pathol (2005) 0.81
Cytokines and chemokines in the vitreous fluid of eyes with uveal melanoma. Invest Ophthalmol Vis Sci (2012) 0.81
Anti-angiogenic therapy in uveal melanoma. Dev Ophthalmol (2011) 0.81
Retinoic acid elicits cytostatic, cytotoxic and immunomodulatory effects on uveal melanoma cells. Cancer Immunol Immunother (2006) 0.81
In vivo confocal microscopy and histopathology of the conjunctiva in trachomatous scarring and normal tissue: a systematic comparison. Br J Ophthalmol (2013) 0.81
High levels of Hdmx promote cell growth in a subset of uveal melanomas. Am J Cancer Res (2012) 0.80
Genetics of primary intraocular tumors. Ocul Immunol Inflamm (2012) 0.80
Rapid up-regulation of cyclooxygenase-2 by 5-fluorouracil in human solid tumors. Anticancer Drugs (2005) 0.80
The chemosensitivity profile of retinoblastoma. Recent Results Cancer Res (2003) 0.80
ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion. Pigment Cell Melanoma Res (2014) 0.80
Analysis of inflammatory cells in uveal melanoma after prior irradiation. Invest Ophthalmol Vis Sci (2013) 0.79
Measuring gene expression from cell cultures by quantitative reverse-transcriptase polymerase chain reaction. Methods Mol Biol (2011) 0.79
Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth. Mol Vis (2008) 0.78
Reflex and steady state tears in patients with latent stromal herpetic keratitis. Invest Ophthalmol Vis Sci (2002) 0.78
Isolation and culture of colon cancer cells and cell lines. Methods Mol Biol (2011) 0.78
Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors. Anticancer Drugs (2004) 0.78